Cargando…
Pegcetacoplan ‐ a novel C3 inhibitor for paroxysmal nocturnal hemoglobinuria
Autores principales: | Rehan, Syeda Tayyaba, Hashmi, Mahnoor Rehan, Asghar, Muhammad Sohaib, Tahir, Muhammad Junaid, Yousaf, Zohaib |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9059189/ https://www.ncbi.nlm.nih.gov/pubmed/35509414 http://dx.doi.org/10.1002/hsr2.512 |
Ejemplares similares
-
Safety and efficacy of pegcetacoplan in paroxysmal nocturnal
hemoglobinuria
por: Wong, Raymond S.M.
Publicado: (2022) -
Pegcetacoplan controls hemolysis in complement inhibitor–naive patients with paroxysmal nocturnal hemoglobinuria
por: Wong, Raymond Siu Ming, et al.
Publicado: (2023) -
C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab
por: de Castro, Carlos, et al.
Publicado: (2020) -
Pegcetacoplan in paroxysmal nocturnal hemoglobinuria: A systematic review on efficacy and safety
por: Shah, Sangam, et al.
Publicado: (2022) -
Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria
por: Wong, Raymond S. M., et al.
Publicado: (2022)